BEIJING, April 25 (Xinhua): Chinese pharmaceutical giant Sinopharm has commenced phase-1 and phase-2 clinical trials for its new recombinant vaccine against Covid-19 in central China's Henan Province since Saturday (April 24).
Developed by the China National Biotec Group (CNBG), a Sinopharm's bioscience subsidiary, the vaccine obtained a clinical research permit from the National Medical Products Administration on April 9.
Already a subscriber? Log in.
Save 30% for ads-free and full access now!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
